BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2896952)

  • 1. Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy.
    Husband DJ; Watkin SW
    Lancet; 1988 May; 1(8594):1116. PubMed ID: 2896952
    [No Abstract]   [Full Text] [Related]  

  • 2. Encephalopathy with rapid infusion ifosfamide/mesna.
    Perren TJ; Turner RC; Smith IE
    Lancet; 1987 Feb; 1(8529):390-1. PubMed ID: 2880199
    [No Abstract]   [Full Text] [Related]  

  • 3. Avoiding ifosfamide/mesna encephalopathy.
    Meanwell CA; Kelly KA; Blackledge G
    Lancet; 1986 Aug; 2(8503):406. PubMed ID: 2874408
    [No Abstract]   [Full Text] [Related]  

  • 4. Ifosfamide/mesna encephalopathy.
    McCallum AK
    Lancet; 1987 Apr; 1(8539):987. PubMed ID: 2882385
    [No Abstract]   [Full Text] [Related]  

  • 5. Irreversible encephalopathy with ifosfamide/mesna.
    Salloum E; Flamant F; Ghosn M; Taleb N; Akatchereian C
    J Clin Oncol; 1987 Aug; 5(8):1303-4. PubMed ID: 3114437
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe renal failure following high-dose ifosfamide and mesna.
    Willemse PH; de Jong PE; Elema JD; Mulder NH
    Cancer Chemother Pharmacol; 1989; 23(5):329-30. PubMed ID: 2495864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal encephalopathy with ifosfamide/mesna.
    Verdeguer A; Castel V; Esquembre C; Ferris J; Fernandez JM; Ruiz JG
    Pediatr Hematol Oncol; 1989; 6(4):383-5. PubMed ID: 2518327
    [No Abstract]   [Full Text] [Related]  

  • 8. Ifosfamide/mesa and encephalopathy.
    Cantwell BM; Harris AL
    Lancet; 1985 Mar; 1(8431):752. PubMed ID: 2858016
    [No Abstract]   [Full Text] [Related]  

  • 9. [Encephalopathy caused by an ifosfamide-mesna combination].
    Beuzeboc P; Dorval T; Garcia-Giralt E; Jouve M; Livartowski A; Palangie T; Scholl S; Pouillart P
    Presse Med; 1988 Apr; 17(12):591-2. PubMed ID: 2967486
    [No Abstract]   [Full Text] [Related]  

  • 10. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
    Steger GG; Dittrich C; Schlappack O; Mader R; Herold C; Brade WP; Keller A; Moser K
    J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nursing implications in the administration of ifosfamide and mesna.
    Richters JE
    Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534
    [No Abstract]   [Full Text] [Related]  

  • 12. Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity.
    Ghosn M; Carde P; Leclerq B; Flamant F; Friedman S; Droz JP; Hayat M
    Bull Cancer; 1988; 75(4):391-2. PubMed ID: 3132998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide/mesna and hematuria.
    Pratt CB; Goren MP
    Cancer Treat Rep; 1987 Nov; 71(11):1124-5. PubMed ID: 3119210
    [No Abstract]   [Full Text] [Related]  

  • 14. Ifosfamide, mesna, and encephalopathy.
    Lancet; 1985 Jun; 1(8442):1398-9. PubMed ID: 2861351
    [No Abstract]   [Full Text] [Related]  

  • 15. Ifosfamide/mesna nomogram and serum albumin.
    Hill PG; Harrop JS
    Lancet; 1986 Oct; 2(8513):986. PubMed ID: 2877171
    [No Abstract]   [Full Text] [Related]  

  • 16. Encephalopathy associated with ifosphamide/mesna therapy.
    Meanwell CA; Blake AE; Latief TN; Blackledge G; Mould JJ; Blake DR; Shaw IC; Honigsberger L; Spooner D; Williams AC
    Lancet; 1985 Feb; 1(8425):406-7. PubMed ID: 2857462
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
    Sanchiz F; Milla A
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of ifosfamide/mesna associated encephalopathy.
    Meanwell CA; Blake AE; Kelly KA; Honigsberger L; Blackledge G
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):815-9. PubMed ID: 3095121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose ifosfamide with mesna uroprotection: a phase I study.
    Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
    J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
    Hilgard P; Burkert H
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1451-2. PubMed ID: 6437825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.